- COVIXYL-V (pronounced ko vik sil V) nasal spray is intended for use in helping to prevent SAR-CoV-2 infection.
- The nasal spray works by creating a physical barrier that prevents the virus from taking hold of the surface in the nasopharynx. This barrier mechanism has been proved through in vitro testing performed by reputable BSL-3 laboratory located in WY.
- The use of the nasal spray is particularly effective because it targets the nasopharynx which has been identified as the main entry point for the virus.
- The research that lead to this extraordinary breakthrough in medicine and public health has been supported by the National Cancer Institute (NCI), an organization under the auspices of the National Institute of Health (NIH). Salvacion was selected to be awarded an accolade in June 2021 by NCI for its development of the COVIXYL-V nasal spray
- In vitro study with rVSV-SARS-CoV-2 model proved that the virus is 99.99% inhibited at low concentration.
- In vivo study with Syrian hamster model, the same model Pfizer and Modena applied for vaccine development, performed by BSL-3 laboratory demonstrated that COVID-19 is 99.99% inactivated with no adverse events found following the administration.
- The unique technology of COVIXYL-V is filed to international PCT patent (PT/US20/55772).
- The active substance, Ethyl Lauroyl Arginate Hydrochloride (ELAH), is listed as a Generally Recognized as Safe (GRAS) ingredient by Food and Drug Administration (FDA) as safe to use in food and other over-the-counter products in the US, EU, UK and Germany.
- ELAH has been extensively studied in toxicity, metabolism and effectiveness in vitro and in vivo.These studies demonstrated that it has no metabolic, pharmacological or immunologic action against the human body.
- This product has been submitted to the FDA for Pre-Emergency Use Authorization and is pending approval for commercial use by the general public in the U.S.
